Antibe Therapeutics (QB) Stock Price - ATBPF

-0.0167 (-3.43%)
Best deals to access real time data!
Small Cap Pro
Monthly Subscription
for only
Canna Trader Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Antibe Therapeutics Inc (QB) ATBPF OTCMarkets Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
-0.0167 -3.43% 0.47 0.4649 0.4796 0.476 0.4867 16:30:01
Bid Price Ask Price Spread Spread % News
0.40 0.80 0.40 50.0% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
28 49,166 $ 0.474119 $ 23,311 170,775 0.19445 - 0.5143
Last Trade Time Type Quantity Stock Price Currency
15:38:45 1,000 $ 0.47 USD

Antibe Therapeutics (QB) Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 135.85M 289.03M $ -7.43M - - 240.17M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
131.99k $ - 0.00% - -

more financials information »

Antibe Therapeutics (QB) News

Loading Messages....

Latest ATBPF Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ATBPF Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.4630.504810.4630.4879082126,2200.0071.51%
1 Month0.386950.51430.35380.451877264,9810.0830521.46%
3 Months0.29140.51430.277750.402938181,7120.178661.29%
6 Months0.293740.51430.24650.3627546152,7390.1762660.01%
1 Year0.2070.51430.194450.3044963145,0740.263127.05%
3 Years0.16980.59930.06090.2797617100,7280.3002176.8%
5 Years0.13330.59930.06090.276885296,0220.3367252.59%

Antibe Therapeutics (QB) Description

Antibe develops safer, non-addictive medicines for pain and inflammation. Antibe's technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe's lead drug ATB-346 targets the global need for a safer, non-addictive drug for chronic pain and inflammation. ATB-352, the second drug in Antibe's pipeline, targets the urgent global need for a non-addictive analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin. Citagenix Inc., an Antibe subsidiary, is a market leader and worldwide distributor of regenerative medicine products for the dental marketplace.

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.